Olverembatinib Shows Promise in TKI-Resistant CML and Ph+ ALL
Olverembatinib has demonstrated antitumor activity in patients with chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia.
Diagnosis & Disease Information
ASH 2022: MCL Trials Break New Ground, May Change Practice
Mantle cell lymphoma trials presented at ASH 2022 have broken new ground, shown promising results, and may change practice, according to researchers.
ASH 2022: Promising Results in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma
The MonumenTAL-1, MajesTEC-2, OPTIMUM/MUKnine, and GMMG-CONCEPT trials have shown promising results for patients with newly diagnosed or relapsed/refractory multiple myeloma.
Delaying HSCT More Than 4 Weeks After COVID-19 Diagnosis May Decrease Risk of Death
Undergoing HSCT within 4 weeks of SARS-CoV-2 infection is associated with an increased risk of death at 90 days after HSCT, real-world data suggest.
AML Research From ASH 2022: Novel Combinations and Evidence That “Less is More”
AML research presented at ASH 2022 highlighted promising combination regimens and suggested that some patients may benefit from less intensive treatment.
ASH 2022: New Findings in CLL
Research in patients with CLL showed that zanubrutinib can outperform ibrutinib, a triplet is effective for high-risk CLL, cell death may predict the depth of response, and a CAR T-cell therapy is likely not an option for CLL patients.
Dexamethasone-Sparing Regimen Shows Promise in Frail Patients With MM
A dexamethasone-sparing treatment strategy is safe and effective for frail patients with newly diagnosed multiple myeloma, according to researchers.
Frontline Regimens for MM Are Similar Across the World; Later Lines of Treatment Vary
Worldwide, bortezomib-based triplets are the most common frontline treatment for multiple myeloma, but regimens used in later lines vary.
ASH 2022: Trials Show Promising Results in Follicular Lymphoma
Results from 4 trials presented at ASH 2022 may help inform the treatment of newly diagnosed and relapsed/refractory follicular lymphoma.
PTCy Plus Tacrolimus and MMF “Should Be Standard” GVHD Prophylaxis in RIC PBSCT
PTCy plus tacrolimus and MMF should be standard GVHD prophylaxis in adults who receive a well-matched PBSCT after RIC, according to researchers.
- Loading...
Loading...
Next post in ASH 2022
Loading... 
Loading...